Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
41 studies found for:    " February 18, 2009":" March 20, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
Conditions: HIV/AIDS;   HIV Infections
Interventions: Drug: darunavir;   Drug: Ritonavir;   Drug: Etravirine
2 Completed Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)
Conditions: HIV;   HIV Infections
Interventions: Biological: V526;   Biological: Comparator: Placebo to V526
3 Completed A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)
Conditions: HIV-1;   HIV Infections
Interventions: Biological: V520;   Biological: Comparator: V520 (1x10^9 vp/d);   Biological: Comparator: V520 (1x10^10 vp/d);   Biological: Comparator: Placebo
4 Completed
Has Results
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
Conditions: HIV-1;   HIV Infections
Interventions: Other: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine;   Biological: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose);   Biological: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine
5 Completed A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers
Conditions: HIV;   HIV Infections
Interventions: Biological: Ad35-GRIN/ENV;   Biological: Ad35-GRIN
6 Active, not recruiting Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: DNA plasmid vaccine;   Biological: Recombinant adenoviral serotype 5 (rAD5) vector vaccine;   Biological: DNA vaccine placebo;   Biological: HIV-1 recombinant adenovirus vaccine placebo
7 Completed Evaluating Post-test HIV Counseling Videos for Teens
Conditions: HIV;   HIV Infections
Intervention: Behavioral: Video
8 Completed Safety of Acidform Lubricant in HIV-Uninfected Women
Condition: HIV Infections
Interventions: Drug: Acidform Lubricant;   Drug: HEC gel
9 Completed Training Community Members to Deliver HIV Prevention Programs to Urban Youth
Conditions: HIV;   HIV Infections
Interventions: Behavioral: Be Proud! Be Responsible!;   Behavioral: Becoming A Responsible Teen (BART);   Behavioral: Reducing the Risk
10 Completed Intensive Viral Dynamics Substudy of A5248
Conditions: HIV Infections;   Treatment Naive
Intervention:
11 Completed
Has Results
Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters
Condition: HIV Infection
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Ritonavir;   Drug: Atazanavir;   Drug: Raltegravir;   Drug: Darunavir
12 Completed
Has Results
Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients
Condition: HIV Infections
Intervention:
13 Completed Asha HIV Health Promotion Intervention in India
Condition: HIV Infections
Interventions: Behavioral: ASHA LIFE;   Behavioral: USUAL Care
14 Terminated
Has Results
Minocycline for HIV+ Cognitive Impairment in Uganda
Conditions: HIV-associated Cognitive Impairment;   HIV Infections
Interventions: Drug: minocycline;   Drug: minocycline placebo capsule
15 Recruiting A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
Conditions: HIV;   HIV Infections;   Pregnancy
Interventions: Drug: Darunavir;   Drug: Ritonavir;   Drug: Etravirine;   Drug: Rilpivirine;   Drug: Darunavir/Cobicistat (FDC)
16 Completed Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: AZT+3TC+ABV (Trizivir);   Drug: Switching to LPV/r monotherapy (Kaletra)
17 Completed
Has Results
Combination Pain Therapy in HIV Neuropathy
Conditions: HIV Infections;   Peripheral Neuropathy
Interventions: Drug: Duloxetine;   Drug: Duloxetine placebo;   Drug: Methadone;   Drug: Methadone placebo
18 Completed
Has Results
Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy
Conditions: Herpes Zoster;   HIV Infections
Interventions: Biological: ZOSTAVAX;   Biological: Placebo
19 Active, not recruiting Strategic Timing of Antiretroviral Treatment
Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
20 Withdrawn Raltegravir Activity In Lymphoid Tissues
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: Efavirenz + Tenofovir DF/Emtricitabine;   Drug: Raltegravir + Tenofovir DF/Emtricitabine;   Procedure: Colonoscopy with biopsies;   Procedure: Inguinal Lymph Node Excision

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.